Talaris therapeutics investor relations

Author: sfou

August undefined, 2024

WebTalaris Therapeutics. Erin Stevens. Email. Direct. Cell Processing Associate. United States, Kentucky, Louisville. Talaris Therapeutics. Install ZoomInfo Community App. To get companies and prospects information just run the installation wizard and get the ZoomInfo Community Edition. 1. Install WebOur wholly owned pipeline is currently focused in three therapeutic areas of high unmet need: hematology, cardiovascular disease, and rare diseases. Indication Target Discovery Preclinical Phase I Ph II Ph III Clinical Zerlasiran (SLN360) Cardiovascular Disease Lp (a) SLN124 Polycythemia Vera (PV) Beta Thalassemia TMPRSS6 SLN-COMP-1 SLN-COMP-2

Investors Talaris Therapeutics, Inc

Web20 Oct 2024 · About Talaris Therapeutics ... Investor Contact Chris Brinzey ICR Westwicke [email protected] (339) 970-2843. 1 Elmariah H, Fuchs EJ. Post-transplantation cyclophosphamide to facilitate ... Web7 May 2024 · Talaris Therapeutics Investors. 12 Investors. Talaris Therapeutics has 12 investors. Longitude Capital invested in Talaris Therapeutics's Series B funding round. First funding. Last Funding. Investor. Rounds. Board Seats. Type. Location. 4/18/2024. 10/6/2024. Longitude Capital. 2. Series A, Series B (2024) Venture Capital. chuck lephucke twitter

TALS - Talaris Therapeutics Inc Stock Price Quote - Morningstar

WebThe Talaris team is composed of highly experienced leaders in the fields of immunology, cell therapy, clinical development, manufacturing, and people development. Scott Requadt … WebTalaris Therapeutics Inc is a late-clinical stage biotechnology company. It is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe autoimmune and immune-mediated disorders. WebEmails and Direct Phone Numbers of Cell Processing Associates in United states Search and Find Anyone's Email Address, Direct Phone Number and Much More desk and shelf combo

Talaris Therapeutics - Products, Competitors, Financials, …

WebOur Company. Vera Therapeutics is a clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments that target the source of immunologic diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion ... WebTalaris Therapeutics, Inc. is a cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders ... chuck leonard wabcWeb7 May 2024 · Talaris will also spend about $25 million to continue work on its preclinical programs. Based on these plans, the company calculates that its cash should support operations at least until 2025.... chuckle other term

"WebFind the latest Talaris Therapeutics, Inc. (TALS) stock quote, history, news and other vital information to help you with your stock trading and investing. " - Talaris therapeutics investor relations

Talaris therapeutics investor relations

Talaris Therapeutics - Funding, Financials, Valuation & Investors

WebDevelopment Pipeline. At Amicus we are business led and science driven to deliver meaningful benefits to patients. We believe that our advanced product pipeline and platform technologies uniquely position us at the forefront of developing therapies to potentially address significant unmet needs for devastating rare diseases. About Amicus. Web12 Apr 2024 · 3 Wall Street analysts have issued 12-month target prices for Talaris Therapeutics' stock. Their TALS share price forecasts range from $3.00 to $23.00. On average, they expect the company's share price to reach $13.00 in the next year. This suggests a possible upside of 630.3% from the stock's current price.

Did you know?

WebPress Releases. Media Statements. Year. Search News. Apr 11. Regeneron Announces Investor Conference Presentations. Apr 3. Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2024. Mar 29. WebChief Human Resources Officer at Talaris Therapeutics . Andrew Farnsworth is a Chief Human Resources Officer at Talaris Therapeutics based in Louisville, Kentucky. Previously, Andrew was a Chief Human R esources Officer at CIRCOR. Andrew received a BA degree from Harvard College and a MBA from Tuck School at Dartmouth. Read More

WebTalaris Therapeutics is funded by 14 investors. Viking Global Investors and Eventide are the most recent investors. Funding Rounds Number of Funding Rounds 2 Total Funding Amount $215M Talaris Therapeutics has raised a total of $215M in funding over 2 rounds. Their latest funding was raised on Oct 6, 2024 from a Series B round. Web7 May 2024 · Talaris joins a growing number of biotech firms in the Boston area that have gone public or are planning to do so this year, including Centessa, Werewolf, and Tango Therapeutics, all based in ...

Web4 May 2024 · For life science investors with a patient hold time frame, my opinion is a BUY at up to $17.00 per share. Company and Technology. Louisville, Kentucky-based Talaris was founded to create an ... Web25 Jan 2024 · Talaris Therapeutics Inc is a late-clinical stage biotechnology company. It is developing transformative cell therapies with the potential to eliminate the burden of …

WebThe Investor Relations website contains information about Talaris Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.

Web16 Feb 2024 · Talaris Therapeutics Announces Plans to Explore Strategic Alternatives and Implements Restructuring Plan BOSTON and LOUISVILLE, Ky., Feb. 16, 2024 (GLOBE … desk and shelf artWeb7 Jun 2024 · Talaris will host an investor webcast and conference call on Thursday, June 30, 2024 at 8:00 a.m. ET to discuss its presentations at the American Transplant Congress (ATC) and provide a data ... chuckle park melbourneWeb28 Jul 2024 · Insiders own 14% of Talaris Therapeutics shares, worth about US$27m. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between ... chuck leonard wtvmWebInvestor FAQs Talaris Therapeutics, Inc. Show All. Where is Talaris’ corporate headquarters? We have corporate offices at 93 Worcester Street, Suite 120, Wellesley, MA … desk and shelf background for pcWeb12 Apr 2024 · Investor Relations Regeneron Pharmaceuticals Inc. INVESTORS & MEDIA Investor Relations News: Apr 03 Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2024 View All News Market Cap: Apr 11, 2024 9:56 PM EDT Data Provided by Refinitiv. Minimum 15 minutes … desk and shelf combo ikeaWeb31 Mar 2024 · Investor Relations Talaris Therapeutics Inc TALS Ownership Morningstar Rating Rating as of Mar 31, 2024 Quote Chart Stock Analysis News Price vs Fair Value ... desk and shelves with pipes desk and shelf wallpaper black